| 1 |
30990031 | Proteomic Strategy for Identification of Proteins Responding to Cisplatin-Damaged DNA. | 2019 May 7 |
1 |
| 2 |
25327479 | Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma. | 2015 Jan |
3 |
| 3 |
20851854 | Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. | 2010 Nov 15 |
1 |
| 4 |
11733188 | The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. | 2002 Jan |
1 |
| 5 |
10076573 | Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. | 1999 Jan |
8 |
| 6 |
8616907 | Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin. | 1996 |
1 |
| 7 |
8679707 | Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. | 1996 Jun 7 |
2 |
| 8 |
8975778 | Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA. | 1996 Dec |
3 |
| 9 |
7994594 | Proteins binding to cisplatin-damaged DNA in human cell lines. | 1994 |
2 |
| 10 |
8226934 | Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA. | 1993 Nov 15 |
3 |